Table 2 Relationship of the promoter hypermethylation of RASSF1A with clinicopathological features of HCC
From: Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma
Parameters | No. of studies | Test for association | Test for heterogeneity (Random effect model) | |||
|---|---|---|---|---|---|---|
OR | 95% CI | P | I2 (%) | P | ||
Age (≥ 50 vs.<50) | 6 | 1.74 | [0.82, 3.69] | 0.152 | 0 | 0.622 |
Gender (male vs. female) | 12 | 1.36 | [0.95, 1.96] | 0.094 | 0 | 0.894 |
HBV (positive vs. negative) | 12 | 1.50 | [1.05, 2.14] | 0.026 | 0 | 0.720 |
HCV (positive vs. negative) | 4 | 0.93 | [0.20, 4.26] | 0.928 | 0 | 0.707 |
Tumor number (multiple vs. single) | 4 | 0.80 | [0.47, 1.36] | 0.410 | 13.9 | 0.323 |
Tumor size (≥ 5 cm vs. < 5 cm) | 10 | 1.92 | [1.07, 3.42] | 0.028 | 38.8 | 0.100 |
Liver cirrhosis (Presence vs. Absence) | 9 | 1.06 | [0.60, 1.87] | 0.834 | 55.8 | 0.021 |
AFP level (≥ 20 μg/L vs. < 20 μg/L) | 6 | 1.25 | [0.47, 3.27] | 0.657 | 61.4 | 0.024 |
Histopathological grade (III/IV vs. I/II) | 5 | 1.84 | [0.53, 6.36] | 0.338 | 81.3 | < 0.001 |
Tumor differentiation (poor vs. moderate or well) | 4 | 0.91 | [0.41, 2.02] | 0.820 | 0 | 0.778 |
Portal venous invasion (presence vs. absence) | 4 | 0.61 | [0.16, 2.40] | 0.481 | 81.2 | 0.001 |